Use the hyperlinks, where available to access additional clinical trial information.
Randomized Phase I/II Study of Ablative Radiotherapy +/- MEDI 4736 (Durvalumab) for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer
Initially, 15 eligible patients will receive both intravenously administered Durvalumab and Stereo Ablative Body Radiotherapy (SABR) to assess the safety of the therapies in combination. After the initial safety test eligible patients will either receive both Durvalumab and SABR, or SABR alone. SABR will be administered on Day 0 over a number of fractions (3,4 or 10) with total doses of either 54, 50 or 65 Grays. Durvalumab will be intravenously administered five days before the SABR and on Day 23, then once every 4 weeks. Follow-up CT imaging will be performed 12 weeks post the administration of SABR, with routine CT scans performed as per standard care thereafter.